Effect of Lifestyle Modification Intervention on Antimetabolic Syndrome Drug Treatment Requirement of patients with Metabolic-Syndrome- Associated-Disorders at University of Nigeria Teaching Hospital Ituku Ozalla, Enugu
DOI:
https://doi.org/10.51412/psnnjp.2025.13Keywords:
Immunotoxins, Immune Optimization, Lifestyle Modification, Metabolic Syndrome, TherapeuticsAbstract
Background: Lifestyle modification is the process of gradual adaptation of corrective lifestyle habits such as diet, physical activity, and sleep for the prevention and management of various diseases. Metabolic syndrome encompasses disorders underscored by metabolic irregularities. Nearly 25% of the global population is affected by metabolic syndrome-associated disorders (MSADs), which
account for most medical outpatient visits and drug prescriptions. As therapeutic adjuncts, lifestyle modification interventions may have a substantial impact on anti-metabolic syndrome drug treatment requirements for control of phenotypic expressions of MSADs. The aim of this study is to determine the combined effect of lifestyle modification on MSADs as therapeutic adjuncts.
Materials and Methods: This was a longitudinal study and part of a randomized controlled trial of lifestyle modification intervention for the management of metabolic syndrome-associated disorders approved by the UNTH ethics committee. Collaborating dieticians, medical sociologists, and exercise physiotherapists assigned Lifestyle Modification Scores (LMS) of GOOD=4-5, FAIR=3, and POOR=0-2 to the patients after diet, sleep, and exercise analysis. Anti-metabolic Syndrome Drug Treatment Requirement (ADTR) score was calculated as the total number of defined unitary dosages of anti-metabolic syndrome drugs times adherence +/- 0.1 accordingly for each unitary or decimal increase/decrease from normal values of clinical/laboratory markers of metabolic syndrome-associated disorders.
Results: There was no significant reduction of Actual Drug Treatment (AdhRx) and ADTR scores of study participants with good LMS, although the mean of the scores was lower than that of those with bad LMS (P > 0.05).
Conclusion: We conclude that ADTR scores are useful and valid tools to assess the impact of lifestyle modification that addresses the aetiopathogenic mechanism in MSADs. This enables differentiation between control of phenotypic expression of MSADs by drugs and that due to lifestyle modification.
References
George K, Alberti MM, Paul Z and Jonathan S (2005). The metabolic syndrome—a new worldwide definition. The Lancet, 366 (9491): 1051-1136
Jean JN, Jobert RN, Eric L, Jan RN, Ulrich FN, Anderson TN et al (2000). Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. The Lancet Child & Adolescent Health, 6 (I3): 158 – 170.
Jamali Z, Ayoobi, F, Jalali Z, Bidaki R, Lofti AM, Nadimi-Esmaeli Ali, Khalili P (2024). Metabolic syndrome: a population-based study of
prevalence and risk factors. Sci Rep 14 (1): 3987. https://doi.org/10.1038/s41598-024-54367-4.
Manaf RA, Nawi AM, Tauhid NM. et al (2021). Prevalence of metabolic syndrome and its associated risk factors among staffs in a
Malaysian public university. Scientific Reports, 11 (1) 8132. https://doi.org/10.1038/s41598-021-87248-1.
Grundy SM (2016). Metabolic syndrome update. Trends in Cardiovascular Medicine, 26 (4) 364-373.
Narciso J, Silva AJ, Rodrigues V et al (2019). Behavioral, contextual and biological factors associated with obesity during adolescence: a
systematic review. PLOS one, 14 (4) e0214941.
Thorp AA, Healy GN, Owen N, Salmon J, Ball K, Shaw JE, Zimmet PZ, Dunstan DW (2010). Deleterious associations of sitting time and
television viewing time with cardiometabolic risk biomarkers: Australian Diabetes, Obesity and Lifestyle (AusDiab) study 2004–2005. Diabetes Care, 33 (2) 327-334.
Aron-Wisnewsky J, Clément K (2016). The gutmicrobiome, diet, and links to cardiometabolic and chronic disorders. Nature Reviews Nephrology, 12 (3) 169-181.
Rizzo NS, Sabaté J, Jaceldo-Siegl K, Fraser GE (2011). Vegetarian dietary patterns are associated with a lower risk of metabolic syndrome: the adventist health study 2. Diabetes Care, 34 (5) 1225-1227.
Okafor MT (2024). Personalized nutrition for obesity management. A mini-review. International Journal of Medicine and Health Development, 29 (3) 285-8.
Chijioke CP, Okafor MT, Nubila NI, Onah IC, Chijioke UO, Chigbo NN et al (2024). Personalized Food Avoidance Dietary Approach for Psoriasis and Hypertension: A Case Study and Pilot Trial. Nigerian Journal of Clinical Practice, 27 (10) 1202- 15.
Lam JC and Ip MS (2010). Sleep & the metabolic syndrome. Indian Journal of Medical Research, 131 (2) 206-217.
Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP (2004). Obstructive sleep apnoea is independently associated with an
increased prevalence of metabolic syndrome. European Heart Journal, 25 (9) 735-741.
Okafor MT, Onyebuchukwu QC, Mbah AU (2023). Immune Optimization as a preventive and therapeutic adjunct for management of metabolic syndrome associated disorders: a review of the literature. African Journal of Endocrinology and Metabolism, 13: (1) 1-7.
Chijioke CP, Okafor MT (2021). Commentary Article: Drug treatment requirement as an outcome parameter to measure the efficacy of lifestyle modification in the management of 'metabolic syndrome' associated immune dysfunction disorders. West African Journal of
Pharmacology and Drug Research, 35 (1) 34-35.
Okafor MT, Ghasi SI (2024). Preventive and Therapeutic Adjunctive Roles of Immune Optimization on Inflammatory and Infectious Diseases. A Mini Review. Nigerian Journal of Basic and Clinical Sciences, 21 (3) 185-9.
Chijioke CP, Okafor MT, Okoli UA, Clinton I, Obiefuna AG, Effiong-Essien RC et al (2023). Effect of Diet-Mediated Immune Optimization on Antihypertensive Drug Treatment Requirement. International Journal of Medicine and Health Development, 28(3) 233-239.
Okafor MT, Okoli UA, Anusiem CA, Chijioke CP (2023). Anti-Hypertensive Drug Treatment Requirement of Immune Optimized Study
Participants In A Clinical Longitudinal Study To Improve Immune Functionality. British Journal of Pharmacology, 180: 358.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The Nigerian Journal of Pharmacy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
